Featured Research

from universities, journals, and other organizations

Possible biomarker for Parkinson's disease

Date:
October 7, 2013
Source:
Beth Israel Deaconess Medical Center
Summary:
A study finds that elevated levels of the alpha-synuclein protein can be detected in the skin of Parkinson's disease patients at an early stage.

Although Parkinson's disease is the second most prevalent neurodegenerative disorder in the U.S., there are no standard clinical tests available to identify this widespread condition. As a result, Parkinson's disease often goes unrecognized until late in its progression, when the brain's affected neurons have already been destroyed and telltale motor symptoms such as tremor and rigidity have already appeared.

Now researchers from Beth Israel Deaconess Medical Center (BIDMC) have discovered that an important clue to diagnosing Parkinson's may lie just beneath the skin.

In a study scheduled to appear in the October 29 print issue of the journal Neurology and currently published on-line, the investigators report that elevated levels of a protein called alpha-synuclein can be detected in the skin of Parkinson's patients, findings that offer a possible biomarker to enable clinicians to identify and diagnose PD before the disease has reached an advanced stage.

Parkinson's disease affects more than 1 million individuals throughout the U.S. Diagnosis is currently made through neurological history and examination, often by a patient's primary care physician.

"Even the experts are wrong in diagnosing Parkinson's disease a large percentage of the time," says senior author Roy Freeman, MD, Director of the Autonomic and Peripheral Nerve Laboratory at BIDMC and Professor of Neurology at Harvard Medical School. "A reliable biomarker could help doctors in more accurately diagnosing Parkinson's disease at an earlier stage and thereby offer patients therapies before the disease has progressed."

Alpha-synuclein is a protein found throughout the nervous system. Although its function is unknown, it is the primary component of protein clumps known as Lewy bodies, which are considered the hallmark of Parkinson's disease. There is accumulating evidence that the protein plays a role in Parkinson's disease development.

"Alpha-synuclein deposition occurs early in the course of Parkinson's disease and precedes the onset of clinical symptoms," explains Freeman, who with his coauthors suspected that the protein was elevated in the skin's structures with autonomic innervation.

"Symptoms related to the autonomic nervous system, including changes in bowel function, temperature regulation, and blood pressure control may antedate motor symptoms in Parkinson's patients," he explains. "Skin-related autonomic manifestations, including excessive and diminished sweating and changes in skin color and temperature, occur in almost two-thirds of patients with Parkinson's disease. The skin can provide an accessible window to the nervous system and based on these clinical observations, we decided to test whether examination of the nerves in a skin biopsy could be used to identify a PD biomarker."

To test this hypothesis, the research team enrolled 20 patients with Parkinson's disease and 14 control subjects of similar age and gender. The participants underwent examinations, autonomic testing and skin biopsies in three locations on the leg. Alpha-synuclein deposition and density of cutaneous sensory, sudomotor and pilomotor nerve fibers were measured.

As predicted, their results showed that alpha-synuclein was increased in the cutaneous nerves supplying the sweat glands and pilomotor muscles in the Parkinson's patients. Higher alpha-synuclein deposition in the nerves supplying the skin's autonomic structures was associated with more advanced Parkinson's disease and worsening autonomic function.

"There is a strong and unmet need for a biomarker for Parkinson's disease," says Freeman. "Alpha-synuclein deposition within the skin has the potential to provide a safe, accessible and repeatable biomarker. Our next steps will be to test whether this protein is present in the cutaneous nerves of individuals at risk for Parkinson's disease, and whether measurement of alpha-synuclein deposition in the skin can differentiate Parkinson's disease from other neurodegenerative disorders."


Story Source:

The above story is based on materials provided by Beth Israel Deaconess Medical Center. Note: Materials may be edited for content and length.


Journal Reference:

  1. N. Wang, C. H. Gibbons, J. Lafo, R. Freeman. -Synuclein in cutaneous autonomic nerves. Neurology, 2013; DOI: 10.1212/WNL.0b013e3182a9f449

Cite This Page:

Beth Israel Deaconess Medical Center. "Possible biomarker for Parkinson's disease." ScienceDaily. ScienceDaily, 7 October 2013. <www.sciencedaily.com/releases/2013/10/131007093743.htm>.
Beth Israel Deaconess Medical Center. (2013, October 7). Possible biomarker for Parkinson's disease. ScienceDaily. Retrieved July 25, 2014 from www.sciencedaily.com/releases/2013/10/131007093743.htm
Beth Israel Deaconess Medical Center. "Possible biomarker for Parkinson's disease." ScienceDaily. www.sciencedaily.com/releases/2013/10/131007093743.htm (accessed July 25, 2014).

Share This




More Health & Medicine News

Friday, July 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

AFP (July 24, 2014) A so-called drugs rehab 'clinic' is closed down in Pakistan after police find scores of ‘patients’ chained up alleging serial abuse. Duration 03:05 Video provided by AFP
Powered by NewsLook.com
Too Few Teens Receiving HPV Vaccination, CDC Says

Too Few Teens Receiving HPV Vaccination, CDC Says

Newsy (July 24, 2014) The Centers for Disease Control and Prevention is blaming doctors for the low number of children being vaccinated for HPV. Video provided by Newsy
Powered by NewsLook.com
New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

    Health News

      Environment News

        Technology News



          Save/Print:
          Share:

          Free Subscriptions


          Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

          Get Social & Mobile


          Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

          Have Feedback?


          Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
          Mobile: iPhone Android Web
          Follow: Facebook Twitter Google+
          Subscribe: RSS Feeds Email Newsletters
          Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins